Sermonix Pharmaceuticals Inc is a privately held biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization. Sermonix’s Lasofoxifene, entering phase 3, is thought to be a potent
third-generation selective estrogen receptor modulator (SERM) with high affinity for the estrogen receptor 1 (ESR1).